Use of stinging cells/capsules for the delivery of active agents to keratinous substances

ABSTRACT

A composition of matter comprising an agent beneficial to a non-skin keratinous substance and at least one stinging capsule and methods of use are disclosed.

FIELD AND BACKGROUND OF THE INVENTION

The present invention relates to novel compositions comprising stingingcells or capsules and methods of using same.

Keratin is a fibrous protein that serves as a structural unit forvarious living tissues. Keratin is the major protein component of hair,wool, nails, horn, hoofs, and the quills of feathers. It contains largequantities of the sulfur-containing amino acids, particularly cysteine.The formation of a disulfide bridge between the sulfur atoms on twocysteines on separate polypeptide chains of keratin allows for thecross-linkage of these chains and results in a fairly rigid aggregate.This phenomenon is consistent with the physiological role of keratin,which provides a tough, fibrous matrix for the tissues in which it isfound.

Anatomically, hair comprises three layers, namely, the medulla, cortexand cuticle. The cuticle is the outermost surface of the hair shaft andis composed of a very hard keratinous substance. It consists offlattened platelets of amorphous keratin, wrapped around the hair shaftin several layers, each layer overlapping the adjacent one, progressingfrom the root to the tip of the hair. A cross section of each cuticlescale reveals that it is sub-divided into three further layers, theendocuticle, exocuticle and epicuticle respectively, the latter onebeing the outermost layer.

The medulla is the innermost layer of the hair and is composed of a softkeratin-rich material and its occurrence in human hair appears to bevariable, usually being present in large thick hairs. Lastly, the cortexis the inner bulk of the hair, which forms the main body of the hair.The cortex is disposed between the medulla and the cuticle. It iscomposed of a soft, fibrous, crystalline keratin. It provides strength,color and texture to the hair.

Long-lasting treatment of hair requires that therapeutic and cosmeticagents traverse the cuticle and penetrate the cortex in order to reactwith the keratin inside it and the medulla. Typically, this is achievedby increasing the temperature, or application of an alkaline lotion suchas ammonia, both of which serve to separate the scales of the cuticleenough to allow the chemicals to pass through. After the treatment isfinished the scales gradually close up again.

However, if hair is processed too many times the cuticle scales maynever return to their original tightness and the protection they onceoffered is lost. The hair becomes increasingly porous, and water canthen pass in and out of the cortex. Over-porous hair is dry, and tendsto develop split ends. The damaged cuticle is fragile, and the damageworsens as time goes by. The greater the damage, the more the cortexswells with water whenever the hair is washed, but the more water itloses when it dries. The repeated wetting and drying of the cortexgradually weakens the hair.

Ammonia has an additional disadvantageous since it is a reducing agentand breaks sulfur bridges inside the hair. The elasticity of the hair isdependent on a particular sum of sulfur bridges so that if the ammoniatreatment is too harsh, the hair will lose more sulfur bonds thannecessary causing the hair to harden, lose weight and diameter.

Anti-parasitic agents used to treat the hair are generally providedtopically and are rinsed out with water. Thus, their toxic effects lastonly for the amount of time that the agents are left in the hair.Recurrence of infection is high since it is very difficult to kill allthe parasites at all stages of their life cycle.

Fungal infections of the nail are common throughout the world. Anestimated 2-13% of the population is affected in North America, with atleast 15-20% of those aged 40-60 having one or more fingernails ortoenails infected. Toenails are much more commonly affected thanfingernails. Infections can range from superficial, causing little morethan discoloration, to severe, resulting in loss of the nail togetherwith deformities of the surrounding digit. The incidence of nail fungalinfections has been rising over the past few decades, due to factorssuch as an increased elderly population, increased participation invigorous physical activity while wearing moisture-retaining shoes andsocks, an increase in the number of HIV infected individuals, anincreased incidence of diabetes, and increased use of steroids,antibiotics, and other therapeutics that can suppress immunologicresponses to fungi.

While nail fungus is rarely life threatening, it causes significantpain, inconvenience, embarrassment, emotional distress, and limitationsto manual performance and ambulation. Individuals with moderate tosevere nail fungal infections can lose their ability to perform manyroutine tasks (such as fastening buttons, picking up small objects,walking significant distances) and can lose the ability to performsatisfactorily in their occupations. Due to the unpleasant appearance oftheir hands or feet, these individuals may become sociallyself-conscious and embarrassed, and may avoid intimate or other closecontact with people. Loss of self-esteem, anxiety, and depressioncommonly result from moderate to severe cases of fungal nail infection.

At present, topical treatments for nail fungus are rarely effective.Although some oral antifungal therapies have moderate efficacy, theyalso pose significant risks of toxic reactions, and many patients wouldprefer local treatments to systemic treatments.

There thus remains a need for improved methods and devices for deliveryof therapeutic and cosmetic agents into keratinous substances such asthe hair and nail.

“Stinging cells” (e.g. cnidocytes, nematocytes and the like) or“stinging capsules” (e.g., cnidocysts, nematocysts and polar capsules)isolated therefrom have been proposed as suitable agents for tissuedelivery of a therapeutic or cosmetic agents [U.S. Pat. Nos. 6,923,976and 6,613,344 and U.S. Pat. App. No. 20040224013]. Cnidaria (hydras, seaanemones, jellyfish and corals) are aquatic animals, which possess avariety of compounds which are stored and delivered via specializedcapsules (cnidocysts), which form a part of specialized cells termedstinging cells (cnidocytes, nematocytes, ptychocytes and the like). Thestinging capsules are hard and dense and filled with liquid containing ahighly folded, inverted tubule which may also feature specializedstructures such as shafts, barbs, spines, and/or stylets. In nature, thecnidocyst discharges and releases its tubule into tissue followingphysical or chemical triggering.

Discharge is initiated by a rapid osmotic influx of water whichgenerates an internal hydrostatic (liquid) pressure of 150 atmospheresforcing capsule rupture and ejection of the tubule [Holstein, T., andTardent, P. (1984) Science, 223(4638), 830-3]. During ejection, the longcoiled and twisted tubule is averted and its length increases by 95%.Accelerating at 40,000 g, the tubule untwists to generate a torqueforce, which rotates the tubule several times around its axis. Thesemechanical processes generate a powerful driving force, which enablesefficient delivery of the compounds, the toxins and enzymes storedwithin the capsule [Lotan et al., 1995 Nature, 375(6531), 456: Lotan etal., 1996 J Exp Zool, 275(6), 444-51; Tardent 1995, BioEssays, 17(4),351-362]. This process, which occurs within microseconds, is among themost rapid exocytosis events in biology [Holstein, T., and Tardent, P.(1984) Science, 223(4638), 830-3].

The Cnidaria family which encompasses 10,000 known species includessedentary single or colonial polyps and pelagic jellyfish. In some ofthese species, cnidocytes account for more than 45% of the cells present[Tardent 1995, BioEssays, 17(4), 351-362].

There are at least three dozen known types of cnidocysts (also termedcnidae) including more than 30 varieties of nematocysts found in mostCnidaria and spirocysts, and ptychocysts found mainly in the Cnidariaclass Anthozoa [Mariscal 1974, Coelenterate biology: reviews and newperspectives, Academic Press, New York.].

U.S. Pat. Appl. No. 20040224013 and U.S. Pat. Nos. 6,923,976 and6,613,344 to the present author teach use of stinging cells for in vivoadministration of an active agent into the hair follicle via the skin ofthe scalp and into the nail via the skin of the cuticle. Penetration ofliving skin tissue, as taught by U.S. Pat. Appl. No. 20040224013 andU.S. Pat. Nos. 6,923,976 and 6,613,344, as opposed to the dead cells ofthe hair shaft or nail, limits the number of active agents which may beused. Furthermore, for local treatment it is preferred not to treat theskin as the active agents may enter the systemic circulation therebyincreasing the incidence of adverse side effects. Penetration into theskin may also be associated with pain. In addition, some treatments,such as hair dyes and anti-parasitic, anti insect agents are noteffective when delivered via the skin.

There is thus a widely recognized need for, and it would be highlyadvantageous to have a non-harmful and non-invasive method of treatingkeratinous substances such as hair and nails.

SUMMARY OF THE INVENTION

According to one aspect of the present invention there is provided amethod of delivering an active agent into a keratinous substance, themethod comprising applying a composition comprising the active agentdisposed in or around at least one stinging capsule to an outer surfaceof a non-skin keratinous substance and triggering a discharge of the atleast one stinging capsule to thereby deliver the active agent into thenon-skin keratinous substance.

According to another aspect of the present invention there is provided amethod of delivering an active agent into a keratinous substance, themethod comprising applying a composition including, at least one activeagent onto an outer surface of a non-skin keratinous substance, applyingat least one stinging capsule to the outer surface of the non-skinkeratinous substance and triggering a discharge of the at least onestinging capsule to thereby deliver the active agent into the keratinoussubstance.

According to yet another aspect of the present invention there isprovided a method of delivering an active agent into a keratinoussubstance, the method comprising preconditioning a non-skin keratinoussubstance by administering into the non-skin keratinous substance atleast one stinging capsule and triggering a discharge of the at leastone stinging capsule to thereby deliver tubule of the at least onestinging capsule into the non-skin keratinous substance thuspreconditioning the non-skin keratinous substance for subsequentdelivery of the active agent and subsequently administering the activeagent onto the non-skin keratinous substance, thereby effecting thedelivery of the active agent into the keratinous substance.

According to further features in preferred embodiments of the inventiondescribed below, the active agent and the active substance areidentical.

According to still further features in the described preferredembodiments the active agent and the active substance are non-identical.

According to still another aspect of the present invention there isprovided a composition of matter comprising an agent beneficial to anon-skin keratinous substance and at least one stinging capsule.

According to further features in preferred embodiments of the inventiondescribed below, the active agent is a therapeutic agent.

According to still further features in the described preferredembodiments the therapeutic agent is selected from the group consistingof a drug, an antiparasitic agent, a nucleic acid construct, a vaccine,a hormone, an enzyme and an antibody.

According to still further features in the described preferredembodiments the active agent is a cosmetic agent.

According to still further features in the described preferredembodiments the cosmetic agent is selected from the group consisting ofa dye, a vitamin, a perfume, a fragrance, a sun screen and aconditioner.

According to still further features in the described preferredembodiments the keratinous substance is selected from the groupconsisting of a hair shaft, a nail and a horn.

According to still further features in the described preferredembodiments the composition is formulated in a topical compositionselected from the group consisting of a powder, a gel, a cream, anointment, a paste, a lotion, a milk, a suspension, an aerosol, a spray,a foam and a serum.

According to still further features in the described preferredembodiments the topical composition is administered onto the non-skinkeratinous substance using an applicator.

According to still further features in the described preferredembodiments the topical composition further comprises an orientation andproximity agent.

According to still further features in the described preferredembodiments the agent beneficial to a non-skin keratinous substance is atherapeutic agent or a cosmetic agent.

According to still further features in the described preferredembodiments the therapeutic agent is selected from the group comprisingan anti-lice/nit agent, an anti- dandruff agent and an antifungal agent,an anti-insect agent and an anti-bacterial agent.

According to still further features in the described preferredembodiments cosmetic agent is selected from the group consisting of ahair dye, a sun-screen, a nail dye, a fragrance and a hair perfume.

The present invention successfully addresses the shortcomings of thepresently known configurations by providing a method of penetratingkeratinous substances, such as hair and nails, for the delivery ofactive agents.

Unless otherwise defined, all technical and scientific terms used hereinhave the same meaning as commonly understood by one of ordinary skill inthe art to which this invention belongs. Although methods and materialssimilar or equivalent to those described herein can be used in thepractice or testing of the present invention, suitable methods andmaterials are described below. All publications, patent applications,patents, and other references mentioned herein are incorporated byreference in their entirety. In case of conflict, the patentspecification, including definitions, will control. In addition, thematerials, methods, and examples are illustrative only and not intendedto be limiting.

BRIEF DESCRIPTION OF THE DRAWINGS

The invention is herein described, by way of example only, withreference to the accompanying drawings. With specific reference now tothe drawings in detail, it is stressed that the particulars shown are byway of example and for purposes of illustrative discussion of thepreferred embodiments of the present invention only, and are presentedin the cause of providing what is believed to be the most useful andreadily understood description of the principles and conceptual aspectsof the invention. In this regard, no attempt is made to show structuraldetails of the invention in more detail than is necessary for afundamental understanding of the invention, the description taken withthe drawings making apparent to those skilled in the art how the severalforms of the invention may be embodied in practice.

In the drawings:

FIG. 1 is a photomicrograph of a hair strand penetrated by stingingtubules; and

FIG. 2 is a photomicrograph of a nail penetrated by stinging tubules.

DESCRIPTION OF THE PREFERRED EMBODIMENTS

The present invention is of novel compositions comprising stinging cellsor capsules and methods of using same.

Specifically, the present invention can be used for delivering activeagents into a keratinous substance such as a hair shaft or a nail.

Before explaining at least one embodiment of the invention in detail, itis to be understood that the invention is not limited in its applicationto the details set forth in the following description or exemplified bythe Examples. The invention is capable of other embodiments or of beingpracticed or carried out in various ways. Also, it is to be understoodthat the phraseology and terminology employed herein is for the purposeof description and should not be regarded as limiting.

To treat keratinous substances, such as hair and nails in a long-lastingway, therapeutic and cosmetic agents must traverse the tough outerkeratinous layers and penetrate the inner layers. For hair, this istypically achieved by increasing the temperature, or application of analkaline lotion such as ammonia, both of which serve to separate thescales of the cuticle enough to allow the chemicals to pass through.Both these treatments however, are potentially harmful to both thecondition and appearance of the hair.

Nails are treated by topical or systemic application of a therapeuticagent (e.g. anti-fungal agent). At present, topical treatments, howeverare rarely effective. Although some oral antifungal therapies havemoderate efficacy, they also pose significant risks of toxic reactions,and many patients would prefer local treatments to systemic treatments.

The use of stinging capsules/cells from Cnidaria as a means ofdelivering active agents to the hair and nail through the skin isdescribed in U.S. Pat. App. No. 20040224013, and U.S. Pat. Nos.6,613,344 and 6,923,976 to the present inventor. Penetration of livingskin tissue, as opposed to the dead cells of the hair shaft or nail,limits the number of active agents which may be used. Furthermore, forlocal treatment it is preferred not to treat the skin as the activeagents may enter the systemic circulation thereby increasing theincidence of adverse side effects. Penetration into the skin may also beassociated with pain. In addition, some treatments, such as hair dyesand anti-parasitic agents are not effective when delivered via the skin.

While reducing the present invention to practice, the present inventorhas uncovered that stinging capsules/cells can penetrate keratinoussubstances such as hair and nails and thus can be used for the directdelivery of agents into these substances. By penetrating the outer layerof the keratinous substance, active agents applied using stingingcapsules may be more effective at either treating a disease or disorder,or having a cosmetic effect. In addition, the use of stingingcapsules/cells for administration of an active agent allows the outerlayers of the keratinous substances to be exposed to a prolongedtreatment since the active agent will not be rinsed out. Release of theactive agent from the inner layers to the outer layers of the keratinoussubstance will typically be slow due to the inherent nature of thekeratinous substance. Slow release of an active agent minimizes thenumber of applications and time between applications. In addition, slowrelease enables a prolonged treatment, allowing the active agent to beused as a prophylactic.

Thus, according to one aspect of the present invention there is provideda composition of matter comprising an agent beneficial to a non-skinkeratinous substance and at least one stinging capsule.

As used herein, the phrase “a non-skin keratinous substance” refers to akeratin-containing substance which is not skin, disposed as theoutermost protective covering of mammals which includes, but is notlimited to, a hair shaft, a toenail, a fingernail, a hoof, a claw and ahorn. The substance may or may not be part of an organism. The hair maybe human hair including but not limited to body hair (such as arm-pithair), scalp hair, pubic hair, eye brow hair and eye lash hair. The hairmay also be mammalian hair such as fur, wool, bristles, spines orquills.

As used herein the phrase “stinging capsules” refers to the capsules(cnidocysts), which are contained in stinging cells. The phrase“stinging cells” refers to the specialized cells (e.g. cnidocytes ornematocytes) present in, for example, all members of the phylumCnidaria, Myxozoa, and Dinoflagellata. The stinging capsules house thedelivery tubule. The stinging capsules act as microscopic syringes andserve as a prey or defense mechanism. The stinging capsule is a hardeneddense capsule filled with liquid, containing a highly folded invertedtubule which sometimes features specialized structures such as shafts,barbs, spines, and/or stylets.

The stinging capsule according to the teachings of the present inventioncan be an isolated stinging capsule or alternatively it can form a partof a stinging cell. In any case, the stinging capsule or cell is derivedfrom an organism of the phylum Cnidaria, Myxozoa, or Dinoflagellata.

The stinging cell or capsule utilized by the present invention ispreferably derived from an organism of the class Anthozoa, Hydrozoa orScyphozoa. More specifically, the stinging cell/capsule utilized by thepresent invention can be derived from, for example, subclassesHexacorallia or Octocorallia of the class Anthozoa, (mostly sea anemoneand corals), subclasses Siponophora or Hydroida of the class Hydrozoa,or from subclasses Rhisostomeae or Semastomeae of the class Scyphozoa.

Stinging capsules from such organisms include toxins, which arenon-toxic to humans, and other mammals. As such, these stinging cells orcapsules isolated therefrom are ideally suited for safe and efficientdelivery of a therapeutic or cosmetic agent into mammalian tissue.

It will be appreciated that the use of stinging cells from organismswhich sequester toxins that are not fatal but cause only minorirritations to, for example, mammals, is also envisioned by the presentinvention.

In addition, stinging cells from other sources can also be utilized bythe present invention provided inactivation of the endogenous toxin iseffected prior to use.

Such inactivation can be effected via one of several methods, includingbut not limited to, temperature or chemical denaturation, enzymaticinactivation or ligand inactivation (e.g., Fab fragment of an antibody).

As is demonstrated in U.S. Pat. No. 6,613,344, toxins endogenous tocnidocysts can be efficiently and easily inactivated by incubatingisolated cnidocysts at 45° C. for several hours. Alternatively,incubation at a high temperature of 70-95° C. for several minutes canalso be utilized by the present invention.

As demonstrated in U.S. Pat. No. 6,613,344, incubation of cnidocysts at45° C. for 22 hours does not damage or trigger activation of thecnidocyst. Such conditions are effective in denaturing polypeptidesstored within the cnidocyst, such as the polypeptide toxins and enzymesdelivered by the tubule of the cnidocyst. It will be appreciated thatsince organisms of, for example, the phylum Cnidaria habitat aquaticenvironments, which are characterized by temperatures well below 30° C.,polypeptides stored within their stinging capsules can be denatured viaincubation in temperatures well above 30° C.

The stinging cell or the stinging capsule of the present invention canbe isolated from a cell extract prepared from organs or parts of anorganism, which contain the stinging cells (for example a whole hydra,tentacles or filaments). Alternatively, stem cells, which give rise tocnidocytes or cnidocysts, can be isolated and cultured or utilizeddirectly.

The main differences between the stinging cells are in their capsuleshape and size and in their tubule dimensions. Examples of speciescontaining different tubules include but are not limited to Rhopilemanomadica (400 μm hollow tubule length with tiny hollow barbs), Hydravulgaris, Hydra hymanae, Metridium senile (200 μm tubule length),Nematostella vectensis (200 μm tubule length), Rhodactis rhodostoma (9mm tubule length), Heliofungia actiniformis (1000 μm tubule length) andAiptasia diaphana (150 μm tubule length).

It will be appreciated that organs, tentacles, or parts of an organism,and the whole organism (hydra for example), which contain the stingingcells can be used without the need for prior isolation of individualstinging cells or for isolation of the capsules from the cells.

As is mentioned hereinabove, the compositions of the present inventionalso include a therapeutic or cosmetic agent suitable for use innon-skin keratinous tissue.

Such agents can be disposed in or around the stinging cell/capsule.According to one preferred embodiment of the present invention, thetherapeutic or cosmetic agent is disposed within the liquid stored inthe stinging cell or the stinging capsule. In such a case, the stingingcell or the isolated capsule is loaded with the therapeutic or cosmeticagent via any one of several methods generally known in the art such as,but not limited to, diffusion, electroporation, liposome fusion,microinjection and the like.

Alternatively and according to another preferred embodiment of thepresent invention, the therapeutic or cosmetic agent is disposed in aliquid surrounding the stinging cell or the isolated capsule. In such acase, the stinging capsule's natural mechanism of osmotically collectingliquid from the environment following triggering pumps the therapeuticor cosmetic agent into the stinging cell just prior to or during thedischarge. Since the surrounding liquid is pumped into the cnida underextremely high pressures over a short period of time it is highlyplausible that high molecular weight molecules, such as polypeptidespolynucleotides and other complex molecules can penetrate the capsuleand be delivered via the tubule upon discharge.

In any case, since a stinging capsule is highly permeable to water andmolecules, therapeutic or cosmetic agent loading prior to or duringdischarge can be easily achieved.

Prior art studies which concentrated on deciphering the permeability andfunctionality of stinging capsules have shown that alkali ions,monovalent ions, divalent ions, or small organic cations such as Tris+or choline+, penetrate cnidocysts and accumulate inside withoutaffecting the properties of the stinging cell or capsule. Studiesperformed by Lubbock & Amos in order to understand the effect of calciumon capsule discharge (1981) have shown that in the predischarged statethe cnida wall is permeable to water and to charged molecules ofrelatively low molecular weight like bromophenol blue (MW 670) andfluoresceinate (MW 376). Hidaka, who investigated of the mechanism ofcapsule discharge (1992, 1993), demonstrated that cnidocysts stainedwith toluidine blue (MW 306) released the blue stain through the tubulewhen discharged leaving the capsule completely clear.

Thus, short polypeptides, hormones, or any low molecule weight agentscan be loaded into stinging cells through simple diffusion. These activecompounds can be stored in the stinging capsule and injected into thetarget substance upon discharge.

Examples of therapeutic agents beneficial to hair include, but are notlimited to anti lice agents, an anti-nit agents (or combination thereof)other anti-insect agents, or anti-dandruff agents. Examples ofanti-lice/anti-nit agents are pyrethroid-based pediculicides, lindaneand malathion.

A therapeutic agent beneficial to nails may be an antifungal agent, anantibacterial agent or an antiviral agent. Examples of anti-fungalagents which may be used according to this aspect of the presentinvention include, but are not limited to Polyenes (e.g. Nystatin),Imidazoles (e.g. Clotrimazole, Econazole, Ketoconazole, Miconazole,fluconazole and itraconazole), terbinafine, ciclopirox, griseofulvin,and Thiocarbamates (e.g. Tolciclate and Tolnaftate).

Examples of hair cosmetic agents which may be used according to thisaspect of the present invention include, but are not limited to a hairdye, a hair conditioner, a vitamin, amino acids, a sun-screen (includingchemical, biological and physical sun screens and filters), anantiperspirant, a deodorant and a perfume or fragrance.

Examples of nail cosmetic agents which may be used according to thisaspect of the present invention include, but are not limited to, a naildye, a nail growth promoter, a nail hardener and a nail strengthener anda perfume or fragrance.

The compositions of the present invention may further comprise anorientation and proximity agent.

The orientation and proximity agent is selected for positioning at leastone stinging capsule/cell in intimate proximity with the keratinoussubstance and orientating it such that the opening tip of the stingingcapsule (termed the operculum) from where the tubule dischargessubstantially faces the keratinous substance.

As used herein, the phrase “in intimate proximity with the substance”refers to a range of distances from touching the substance to thefurthest distance from the substance that the tubules are still able topenetrate.

As described in U.S. pat. app. Ser. No. 11/108,662, the stingingcapsules have asymmetric charge/structure characteristics, such that theopening tip is positively charged and the opposite end is not. Thus, byusing specific agents capable of binding to the opening tip on one handand a keratinous substance on the other, the capsules can be orientatedso that a high proportion of stinging cells come into physical contactwith a keratinous substance, thereby enhancing subsequent delivery of anactive agent. Specifically, the opening tip is orientated, such that itsubstantially faces the keratinous substance. The term “substantiallyfacing the keratinous substance” as used herein describes any angle ofthe opening tip which will allow penetration of the tubule into thekeratinous substance. Preferably, the opening tip may be perpendicularto the tissue surface (at an angle of 90°) allowing for the greatestsurface area of the opening tip to be in touch with the substance'ssurface. However, the opening tip may also be orientated at other anglesto the keratinous substance.

Preferably, the orientation and proximity agent is a negatively chargedpolymer, or at least partially negatively charged, which interacts withthe positively charged opening tip. Examples of negatively chargedpolymers that may be used in the present invention include, but are notlimited to synthetic anionic polymers such as polyacrylic acid (PAA),poly saccharines, such as alginic Acid, Na alginate, hydroxy propylmethyl cellulose, carboxy methyl cellulose, and others poly saccharinessuch as gum karaya, gum tragacanth, poly ethylene oxide, poly vinylalcohol, starch, lecithin. The orientation and proximity agent can beamphoteric for example gelatin, caseine and lecitin. The orientation andproximity agent may also serve as an adhesive or bioadhesive e.g. PAA,carbomer, lectin, bacterial fimbrins and invasins. The capsules can bepretreated with the orientation and proximity agents. Alternatively, theorientation and proximity agents can be introduced into the compositionin which the capsules are formulated.

The compositions of the present invention may alternatively or furthercomprise conditioning agents which increase the porosity of thekeratinous substance.

The compositions of the present invention are typically appliedtopically onto the keratinous substances e.g. in a gel. In this way, thenumber of tubules need not be limited to one particular area of thesubstance as is the case with a chip or an array, but may be spread overlarger areas. This may be particularly useful when applying activeagents to treat the hair, for example in treating lice or when applyingcosmetic agents to color or condition the hair.

Alternatively, as described herein below, for more accurate dosing of anactive agent, the stinging capsules can be applied onto a keratinoussubstance using an applicator such as a patch, a cap, a foil, a plaster,a polymer or a pad which can be prepared with an exact quantity ofstinging capsules.

To stabilize the stinging cells/capsules and to possibly enhancetriggering efficiency, the stinging cells/capsules of the presentinvention are preferably included in a pharmaceutical composition. Suchpharmaceutical compositions comprise a carrier. The carrier generallyshould not affect the ability of the stinging cells to dischargefollowing triggering. The pharmaceutical compositions of the presentinvention are generally formulated for topical applications. Examples ofpharmaceutical compositions suitable for topical applications include,but are not limited to powders, gels, creams, ointments, pastes,lotions, milks, suspensions, foams and serums.

Thus, according to the teachings of the present invention stinging cellsor stinging capsules can be utilized for the in vivo or ex vivo deliveryof a therapeutic or cosmetic agent into a keratinous substance.

Delivery of a therapeutic or cosmetic agent according to the presentinvention can be effected by applying a composition comprising stingingcells and an active agent such as those described above to an outersurface of the keratinous substance (e.g., hair). Following application,the stinging cells or the isolated capsules are triggered (as is furtherdescribed hereinbelow) and the therapeutic or the cosmetic agent isthereby delivered by the tubule into the substance.

Alternatively, the therapeutic or cosmetic agent can be applied onto theouter surface of the keratinous substance, followed by application ofstinging cell(s) or stinging capsules to the same region. Upontriggering, the agent is pumped into the stinging cells or into thecapsules (as is further described herein) and the therapeutic or thecosmetic agent is delivered via the tubule into the keratinoussubstance.

Still alternatively, the outer surface of the keratinous substance canbe preconditioned (using either standard delivery methods or stingingcells/capsules) so that it is more amenable to the diffusion through itof active agents. This is effected by tubules which remain in thekeratinous substance following stinging capsule/cell discharge. Thetubules serve as open channels for subsequent delivery of active agents.According to this aspect of the present invention, the tubules may bepreloaded with an active substance which may or may not be identical tothe active agent which is subsequently delivered.

As used herein the phrase “triggering a discharge” refers to theactivation of at least one stinging capsule/cell whereby the tubulecontained within is released and penetrates the keratinous substance.This may be triggered by the active agent itself or by a second agenteither by hydration, a change in pH, by a biochemical change (e.g. anenzyme) or by a chemical change.

Chemical triggering can be mediated by substances such as free andconjugated N-acetylated sugars or low molecular weight amino compoundswhich are known to be detected by at least two classes of stinging cellchemoreceptors. Sodium thiocyanate (NaSCN) is capable of triggeringdischarge of cnidocysts.

In addition, Lubbock and Amos [Nature, 290(5806), 500-1, 1981] haveshown that isolated cnida (cnidocysts) can discharge normally whenplaced in buffered EGTA or 10 mM citrate solution; Weber [Eur J Biochem,184(2), 465-76 (1989)] demonstrated the effect of dithioerthritol orproteases on discharging isolated cnida and Hidaka [Advances inComparative and Environmental Physiology, 15, 45-76 (1993)] discussedvarious agents which can trigger cnida discharge.

Alternatively, discharge may be effected by hydration with a water-basedcomposition such as saline or water, thereby opening channels in thekeratinous substance and enhancing delivery of a subsequent topicallyapplied agent.

Additional objects, advantages, and novel features of the presentinvention will become apparent to one ordinarily skilled in the art uponexamination of the following examples, which are not intended to belimiting. Additionally, each of the various embodiments and aspects ofthe present invention as delineated hereinabove and as claimed in theclaims section below finds experimental support in the followingexamples.

EXAMPLES

Reference is now made to the following examples, which together with theabove descriptions, illustrate the invention in a non limiting fashion.

Generally, the nomenclature used herein and the laboratory proceduresutilized in the present invention include molecular, biochemical,microbiological and recombinant DNA techniques. Such techniques arethoroughly explained in the literature. See, for example, “MolecularCloning: A laboratory Manual” Sambrook et al., (1989); “CurrentProtocols in Molecular Biology” Volumes I-III Ausubel, R. M., ed.(1994); Ausubel et al., “Current Protocols in Molecular Biology”, JohnWiley and Sons, Baltimore, Md. (1989); Perbal, “A Practical Guide toMolecular Cloning”, John Wiley & Sons, New York (1988); Watson et al.,“Recombinant DNA”, Scientific American Books, New York; Birren et al.(eds) “Genome Analysis: A Laboratory Manual Series”, Vols. 1-4, ColdSpring Harbor Laboratory Press, New York (1998); methodologies as setforth in U.S. Pat. Nos. 4,666,828; 4,683,202; 4,801,531; 5,192,659 and5,272,057; “Cell Biology: A Laboratory Handbook”, Volumes I-III Cellis,J. E., ed. (1994); “Culture of Animal Cells—A Manual of Basic Technique”by Freshney, Wiley-Liss, New York (1994), Third Edition; “CurrentProtocols in Immunology” Volumes I-III Coligan J. E., ed. (1994); Stiteset al. (eds), “Basic and Clinical Immunology” (8th Edition), Appleton &Lange, Norwalk, Conn. (1994); Mishell and Shiigi (eds), “SelectedMethods in Cellular Immunology”, W. H. Freeman and Co., New York (1980);available immunoassays are extensively described in the patent andscientific literature, see, for example, U.S. Pat. Nos. 3,791,932;3,839,153; 3,850,752; 3,850,578; 3,853,987; 3,867,517; 3,879,262;3,901,654; 3,935,074; 3,984,533; 3,996,345; 4,034,074; 4,098,876;4,879,219; 5,011,771 and 5,281,521; “Oligonucleotide Synthesis” Gait, M.J., ed. (1984); “Nucleic Acid Hybridization” Hames, B. D., and HigginsS. J., eds. (1985); “Transcription and Translation” Hames, B. D., andHiggins S. J., eds. (1984); “Animal Cell Culture” Freshney, R. I., ed.(1986); “Immobilized Cells and Enzymes” IRL Press, (1986); “A PracticalGuide to Molecular Cloning” Perbal, B., (1984) and “Methods inEnzymology” Vol. 1-317, Academic Press; “PCR Protocols: A Guide ToMethods And Applications”, Academic Press, San Diego, Calif. (1990);Marshak et al., “Strategies for Protein Purification andCharacterization—A Laboratory Course Manual” CSHL Press (1996); all ofwhich are incorpotaed by reference as if fully set forth herein. Othergeneral references are provided throughout this document. The procedurestherein are believed to be well known in the art and are provided forthe convenience of the reader. All the information contained therein isincorporated herein by reference.

Example 1 Penetration into Hair

Methods and Materials

Stinging capsules in a topical formulation (2% Hydroxypropyl cellulosein ethanol) were applied to human hairs. The treated hairs were immersedin water solution containing 0.05% toluidine blue for activation andbetter visualization of the stinging capsules. Following activation, thehairs were thoroughly washed with water. The hairs were observed under astereoscope.

Results

As illustrated in FIG. 1, the stinging capsules penetrated the hair.Penetration was immediate.

Example 2 Penetration into Nails

Methods and Materials

Stinging capsules in a topical formulation (2% Hydroxypropyl cellulosein ethanol) were applied to human finger and toe nail plates. Thetreated nails were immersed in water solution containing 0.05% toluidineblue for activation and better visualization of the stinging capsules.After a few seconds, the nails were thoroughly washed with water. Thenails were observed under a stereoscope.

Results

As illustrated in FIG. 2, the stinging capsules penetrated the nail.

It is appreciated that certain features of the invention, which are, forclarity, described in the context of separate embodiments, may also beprovided in combination in a single embodiment. Conversely, variousfeatures of the invention, which are, for brevity, described in thecontext of a single embodiment, may also be provided separately or inany suitable subcombination.

Although the invention has been described in conjunction with specificembodiments thereof, it is evident that many alternatives, modificationsand variations will be apparent to those skilled in the art.Accordingly, it is intended to embrace all such alternatives,modifications and variations that fall within the spirit and broad scopeof the appended claims. All publications, patents and patentapplications mentioned in this specification are herein incorporated intheir entirety by reference into the specification, to the same extentas if each individual publication, patent or patent application wasspecifically and individually indicated to be incorporated herein byreference. In addition, citation or identification of any reference inthis application shall not be construed as an admission that suchreference is available as prior art to the present invention.

1. A method of delivering an active agent into a keratinous substance,the method comprising: (a) applying a composition comprising the activeagent disposed in or around at least one stinging capsule to an outersurface of a non-skin keratinous substance; and (b) triggering adischarge of said at least one stinging capsule to thereby deliver theactive agent into said non-skin keratinous substance.
 2. The method ofclaim 1, wherein said active agent is a therapeutic agent.
 3. The methodof claim 2, wherein said therapeutic agent is selected from the groupconsisting of a drug, an antiparasitic agent, a nucleic acid construct,a vaccine, a hormone, an enzyme and an antibody.
 4. The method of claim1, wherein said active agent is a cosmetic agent.
 5. The method of claim4, wherein said cosmetic agent is selected from the group consisting ofa dye, a vitamin, a perfume, a fragrance a sun screen and a conditioner.6. The method of claim 1, wherein the keratinous substance is selectedfrom the group consisting of a hair shaft, a nail and a horn.
 7. Themethod of claim 1, wherein said composition is formulated in a topicalcomposition selected from the group consisting of a powder, gel, acream, an ointment, a paste, a lotion, a milk, a suspension, an aerosol,a spray, a foam and a serum.
 8. The method of claim 7, wherein saidtopical composition is administered onto said non-skin keratinoussubstance using an applicator.
 9. The method of claim 7, wherein saidtopical composition further comprises an orientation and proximityagent.
 10. A method of delivering an active agent into a keratinoussubstance, the method comprising: (a) applying a composition including,at least one active agent onto an outer surface of a non-skin keratinoussubstance; (b) applying at least one stinging capsule to said outersurface of said non-skin keratinous substance; and (c) triggering adischarge of said at least one stinging capsule to thereby deliver theactive agent into the keratinous substance.
 11. The method of claim 10,wherein said active agent is a therapeutic agent.
 12. The method ofclaim 11, wherein said therapeutic agent is selected from the groupconsisting of a drug, an anti-parasitic agent, a nucleic acid construct,a vaccine, a hormone, an enzyme and an antibody.
 13. The method of claim10, wherein said active agent is a cosmetic agent.
 14. The method ofclaim 13, wherein said cosmetic agent is selected from the groupconsisting of a dye, a vitamin, a perfume, a fragrance, a sun screen anda conditioner.
 15. The method of claim 10, wherein the keratinoussubstance is selected from the group consisting of a hair shaft, a nailand a horn.
 16. The method of claim 10, wherein said at least onestinging capsule is formulated in a topical composition selected fromthe group consisting of a powder, a gel, a cream, an ointment, a paste,a lotion, a milk, a suspension, an aerosol, a spray, a foam and a serum.17. The method of claim 16, wherein said topical composition isadministered onto said non-skin keratinous substance using anapplicator.
 18. The method of claim 16, wherein said topical compositionfurther comprises an orientation and proximity agent.
 19. A method ofdelivering an active agent into a keratinous substance, the methodcomprising: (a) preconditioning a non-skin keratinous substance by: (i)administering into said non-skin keratinous substance at least onestinging capsule; and (ii) triggering a discharge of said at least onestinging capsule to thereby deliver tubule of said at least one stingingcapsule into said non-skin keratinous substance thus preconditioningsaid non-skin keratinous substance for subsequent delivery of the activeagent; and subsequently (b) administering the active agent onto saidnon-skin keratinous substance, thereby effecting the delivery of theactive agent into the keratinous substance.
 20. The method of claim 19,wherein said active agent is a therapeutic agent.
 21. The method ofclaim 20, wherein said therapeutic agent is selected from the groupconsisting of a drug, an anti-parasitic agent, a nucleic acid construct,a vaccine, a hormone, an enzyme and an antibody.
 22. The method of claim19, wherein said active agent is a cosmetic agent.
 23. The method ofclaim 22, wherein said cosmetic agent is selected from the groupconsisting of a dye, a vitamin, a perfume, a fragrance, a sun screen anda conditioner.
 24. The method of claim 19, wherein the keratinoussubstance is selected from the group consisting of a hair shaft, a nailand a horn.
 25. The method of claim 19, wherein said at least onestinging capsule is formulated in a topical composition selected fromthe group consisting of a powder, a gel, a cream, an ointment, a paste,a lotion, a milk, a suspension, an aerosol, a spray, a foam and a serum.26. The method of claim 25, wherein said topical composition isadministered onto said non-skin keratinous substance using anapplicator.
 27. The method of claim 25, wherein said topical compositionfurther comprises an orientation and proximity agent.
 28. The method ofclaim 19, wherein said at least one stinging capsule is preloaded withan active substance or is in a composition which comprises said activesubstance.
 29. The method of claim 28, wherein said active agent andsaid active substance are identical.
 30. The method of claim 28, whereinsaid active agent and said active substance are non-identical.
 31. Acomposition of matter comprising an agent beneficial to a non-skinkeratinous substance and at least one stinging capsule.
 32. Thecomposition of matter of claim 31, wherein said agent beneficial to anon-skin keratinous substance is disposed in a liquid surrounding, orstored within, said at least one stinging capsule.
 33. The compositionof matter of claim 31, wherein said agent beneficial to a non-skinkeratinous substance is a therapeutic agent or a cosmetic agent.
 34. Thecomposition of matter of claim 33, wherein said therapeutic agent isselected from the group comprising an anti-lice/nit agent, ananti-dandruff agent and an antifungal agent, an anti-insect agent and ananti-bacterial agent.
 35. The composition of matter of claim 33, whereinsaid cosmetic agent is selected from the group consisting of a hair dye,a sun-screen, a nail dye, a fragrance and a hair perfume.
 36. Thecomposition of matter of claim 31, formulated in a topical compositionselected from the group consisting of a powder, a gel, a cream, anointment, a paste, a lotion, a milk, a suspension, an aerosol, a spray,a foam and a serum.
 37. The composition of matter of claim 31, furthercomprising an orientation and proximity agent.